AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2411079 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 24 weeks
Number of subjects: 16
Study 31343446 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (20 U frontal, 20 U glabellar, with/without 24 U in crow's feet)
Number of subjects: 140
Study 31343446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 29654112 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Hz stimulation of the subthalamic nucleus (STN)
Number of subjects: 11
Study 29654112 — intervention group
Group type: COMPARATOR
Intervention: 130 Hz stimulation of the subthalamic nucleus (STN)
Number of subjects: 11
Study 29654112 — intervention group
Group type: COMPARATOR
Intervention: Deep brain stimulation off
Number of subjects: 11
Study 26748531 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF)
Number of subjects: 112
Study 26748531 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 112
Study 26748531 — intervention group
Group type: COMPARATOR
Intervention: Physical Activity (PA)
Number of subjects: 112
Study 25348013 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Worker Health™ program, implemented through monthly 2-hour peer-led meetings.
Number of subjects: 160
Study 25348013 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 160
Study 22964967 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen (17β‐estradiol 1 mg)
Number of subjects: 62
Study 22964967 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg)
Number of subjects: 62
Study 22964967 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy postmenopausal women)
Number of subjects: 62
Study 19921145 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapeutic group training including gait and balance exercises with function‐orientated strengthening (twice weekly over 12 weeks)
Number of subjects: 71
Study 19921145 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 71
Study 16900354 — intervention group
Group type: EXPERIMENTAL
Intervention: Humerus intramedullary nail (IMN)
Number of subjects: 47
Study 16900354 — intervention group
Group type: COMPARATOR
Intervention: Dynamic compression plate (DCP)
Number of subjects: 47
Study 16170945 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide-angle visual flow display
Number of subjects: 16
Study 16170945 — intervention group
Group type: COMPARATOR
Intervention: Full view display
Number of subjects: 16
Study 16170945 — intervention group
Group type: COMPARATOR
Intervention: 20 degrees x 20 degrees central field omission
Number of subjects: 16
Study 16170945 — intervention group
Group type: COMPARATOR
Intervention: 105 degrees area display
Number of subjects: 16
Study 12068250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.8 g/kg in juice)
Number of subjects: 20
Study 12068250 — intervention group
Group type: COMPARATOR
Intervention: Placebo (juice alone)
Number of subjects: 20
Study 10492633 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 68
Study 10492633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 8559203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragweed-extract immunotherapy
Number of subjects: 77
Study 8559203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 2201731 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 24
Study 2201731 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 24
Study 2201731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7281952 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine dermis
Number of subjects: 26
Study 7281952 — intervention group
Group type: COMPARATOR
Intervention: Conventional paste bandaging
Number of subjects: 26
Study 30838896 — intervention group
Group type: EXPERIMENTAL
Intervention: Small head metal-on-metal (SHMoM) THA
Number of subjects: 56
Study 30838896 — intervention group
Group type: COMPARATOR
Intervention: Conventional metal-on-polyethylene (MoP) THA
Number of subjects: 56
Study 30838896 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SHMoM and MoP THA
Number of subjects: 56
Study 30256061 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane-based chemotherapy (4 to 6 cycles)
Number of subjects: 100
Study 30256061 — intervention group
Group type: COMPARATOR
Intervention: Anthracycline-based chemotherapy (4 to 6 cycles)
Number of subjects: 100
Study 28811009 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex group (Group S) received rocuronium 0.6 mg/kg at anesthesia induction and sugammadex 2 mg/kg at skin incision.
Number of subjects: 50
Study 28811009 — intervention group
Group type: COMPARATOR
Intervention: Conventional anesthesia group (Group C) did not receive any NMBA.
Number of subjects: 50
Study 28811009 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Group S and Group C) during facial nerve stimulation.
Number of subjects: 50
Study 26054147 — intervention group
Group type: EXPERIMENTAL
Intervention: Microinjection acupuncture (MIA)
Number of subjects: 90
Study 26054147 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture drug anesthesia (ADA)
Number of subjects: 90
Study 26054147 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 90
Study 26054147 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 24122908 — intervention group
Group type: EXPERIMENTAL
Intervention: TRV130 (0.15 to 7 mg administered intravenously over 1 hour)
Number of subjects: 0
Study 24122908 — intervention group
Group type: EXPERIMENTAL
Intervention: TRV130 (1.5 mg administered as 30, 15, 5, and 1 minute infusions)
Number of subjects: 0
Study 24122908 — intervention group
Group type: EXPERIMENTAL
Intervention: TRV130 (2.2, 4, and 7 mg doses)
Number of subjects: 0
Study 24122908 — intervention group
Group type: EXPERIMENTAL
Intervention: TRV130 (7 mg dose)
Number of subjects: 0
Study 21766228 — intervention group
Group type: EXPERIMENTAL
Intervention: GTP (500 mg GTP/day)
Number of subjects: 171
Study 21766228 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise (60 min/session, three sessions/week)
Number of subjects: 171
Study 21766228 — intervention group
Group type: EXPERIMENTAL
Intervention: GTP + Tai Chi
Number of subjects: 171
Study 21766228 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg starch/day)
Number of subjects: 171
Study 19156563 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered psychotherapeutic tool
Number of subjects: 15
Study 19156563 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 15
Study 17898246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) rehydration
Number of subjects: 36
Study 17898246 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-, gender-, and weight-matched children without dehydration)
Number of subjects: 36
Study 15135261 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 ml of linseed oil (rich in ALA) per day (n=60)
Number of subjects: 90
Study 15135261 — intervention group
Group type: COMPARATOR
Intervention: 15 ml of safflower oil (rich in LA) per day (n=30)
Number of subjects: 90
Study 11684550 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate anticoagulation
Number of subjects: 0
Study 11684550 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin (low-molecular-weight heparin)
Number of subjects: 0
Study 9610754 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone (GH) replacement therapy, mean dose 0.23 ± 0.01 IU/kg/week, divided into daily subcutaneous injections, for 3 years.
Number of subjects: 20
Study 8021731 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin alone (60 mg/m2 i.v. every 3 weeks for eight courses)
Number of subjects: 356
Study 8021731 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus cyclophosphamide (500 mg/m2 i.v. every 3 weeks for eight courses)
Number of subjects: 356
Study 2510460 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise increased hMG dosage (group 1)
Number of subjects: 58
Study 2510460 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose hMG for 2 days followed by constant daily dose (group 2)
Number of subjects: 58
Study 2510460 — intervention group
Group type: COMPARATOR
Intervention: Both groups (group 1 and group 2)
Number of subjects: 58
Study 113803 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine 200 mg/day
Number of subjects: 0
Study 113803 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 150 mg/day
Number of subjects: 0
Study 31354255 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 500 μg once daily for 12 weeks
Number of subjects: 55
Study 31354255 — intervention group
Group type: COMPARATOR
Intervention: Roflumilast 250 μg once daily for 4 weeks, then 500 μg for 12 weeks (dose-escalation)
Number of subjects: 55
Study 28291062 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed CO2 laser
Number of subjects: 240
Study 28291062 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 240
Study 28291062 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 240
Study 25588782 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt containing Lactobacillus rhamnosus GG, Bifidobacterium lactis, and Lactobacillus acidophilus, 200 g/day
Number of subjects: 72
Study 25588782 — intervention group
Group type: COMPARATOR
Intervention: Pasteurised yogurt (placebo)
Number of subjects: 72
Study 25588782 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt
Number of subjects: 72
Study 24035102 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone users during the 'stand-up' test
Number of subjects: 3
Study 24035102 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers during the 'stand-up' test
Number of subjects: 3
Study 24035102 — intervention group
Group type: COMPARATOR
Intervention: Patients with congenital long QT syndrome (LQTS) during the 'stand-up' test
Number of subjects: 3
Study 24035102 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone users
Number of subjects: 3
Study 22185725 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray at 200 μg once daily for 12 weeks
Number of subjects: 43
Study 22185725 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin tablet at 250 mg once daily for 12 weeks
Number of subjects: 43
Study 19523618 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist multiple‐dose protocol (MDP) with OCP pretreatment
Number of subjects: 82
Study 19523618 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist low‐dose long protocol (LP)
Number of subjects: 82
Study 17050637 — intervention group
Group type: EXPERIMENTAL
Intervention: PES (polyelectrolyte-modified polyethersulphone)
Number of subjects: 8
Study 17050637 — intervention group
Group type: COMPARATOR
Intervention: PSU (polysulphone)
Number of subjects: 8
Study 15858956 — intervention group
Group type: EXPERIMENTAL
Intervention: LC‐PUFA supplementation (LF)
Number of subjects: 474
Study 15858956 — intervention group
Group type: COMPARATOR
Intervention: Control (CF)
Number of subjects: 474
Study 15858956 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed (BF)
Number of subjects: 474
Study 12808614 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral cyclosporin (15 mg per kg per day)
Number of subjects: 102
Study 12808614 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (0.2 mg per kg per day)
Number of subjects: 102
Study 12808614 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral cyclosporin
Number of subjects: 102
Study 12808614 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 102
Study 10639695 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (15 mg)
Number of subjects: 32
Study 10639695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 8560050 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (3 micrograms/kg orally 90-120 min before surgery)
Number of subjects: 45
Study 8560050 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg intravenous 1 min before EIT)
Number of subjects: 45
Study 8560050 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 1911017 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride and ranitidine administered simultaneously
Number of subjects: 12
Study 1911017 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine alone
Number of subjects: 12
Study 7323704 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass surgery with a 3:1 or 1:3 jejunoileal ratio
Number of subjects: 34
Study 7323704 — intervention group
Group type: COMPARATOR
Intervention: Control group (before surgery)
Number of subjects: 34
Study 30355090 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 1441
Study 26402730 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated Linoleic Acid (CLA) 3.2 g/day
Number of subjects: 28
Study 26402730 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Olive oil 4 g/day)
Number of subjects: 28
Study 26402730 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CLA and Placebo)
Number of subjects: 28
Study 24290738 — intervention group
Group type: EXPERIMENTAL
Intervention: Imageless navigation system
Number of subjects: 130
Study 24290738 — intervention group
Group type: COMPARATOR
Intervention: Freehand conventional technique
Number of subjects: 130
Study 22552265 — intervention group
Group type: EXPERIMENTAL
Intervention: R1663 (300 mg twice daily or 400 mg once daily for seven days)
Number of subjects: 48
Study 22552265 — intervention group
Group type: EXPERIMENTAL
Intervention: R1663
Number of subjects: 48
Study 20487575 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoghurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1
Number of subjects: 142
Study 20487575 — intervention group
Group type: COMPARATOR
Intervention: Milk
Number of subjects: 142
Study 18407321 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 141
Study 18407321 — intervention group
Group type: COMPARATOR
Intervention: Phenprocoumon
Number of subjects: 141
Study 18407321 — intervention group
Group type: COMPARATOR
Intervention: Acenocoumarol
Number of subjects: 141
Study 15693860 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid paraffin
Number of subjects: 40
Study 15693860 — intervention group
Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 40
Study 11994054 — intervention group
Group type: EXPERIMENTAL
Intervention: entacapone 200 mg four times daily
Number of subjects: 12
Study 11994054 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 10048102 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 mg nicotine patches
Number of subjects: 63
Study 10048102 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 mg nicotine patches
Number of subjects: 63
Study 10048102 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg nicotine patches
Number of subjects: 63
Study 10048102 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 63
Study 10048102 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment conditions
Number of subjects: 63
Study 10048102 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers under age 30
Number of subjects: 63
Study 10048102 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers 30 years or older
Number of subjects: 63
Study 10048102 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed continuous quitters
Number of subjects: 63
Study 10048102 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous abstainers surveyed
Number of subjects: 63
Study 7669957 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal atrial pacing (TAP)
Number of subjects: 50
Study 7669957 — intervention group
Group type: COMPARATOR
Intervention: Gallamine (40 mg intermittent bolus)
Number of subjects: 50
Study 2185293 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 micrograms/day)
Number of subjects: 20
Study 2185293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6119104 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional propranolol (160 mg)
Number of subjects: 12
Study 6119104 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release oxprenolol
Number of subjects: 12
Study 6119104 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 12
Study 6119104 — intervention group
Group type: EXPERIMENTAL
Intervention: Long acting propranolol
Number of subjects: 12
Study 30810976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fire-needle therapy once weekly for 4 weeks plus Oral Huoxue Jiedu Decoction and vaseline cream
Number of subjects: 151
Study 30810976 — intervention group
Group type: COMPARATOR
Intervention: Oral Huoxue Jiedu Decoction and vaseline cream
Number of subjects: 151
Study 28548626 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated EV71 vaccine
Number of subjects: 0
Study 25732161 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (TC; paclitaxel 175 mg/m(2) over 3 hours and carboplatin AUC 5 mg/mL/min on day 1, repeated every 3 weeks)
Number of subjects: 253
Study 25732161 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus cisplatin (TP; paclitaxel 135 mg/m(2) over 24 hours on day 1 and cisplatin 50 mg/m(2) on day 2, repeated every 3 weeks)
Number of subjects: 253
Study 25732161 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (TC)
Number of subjects: 253
Study 23632051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular steroid injections
Number of subjects: 56
Study 23632051 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency denervation
Number of subjects: 56
Study 21967070 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase 0.58 mg injections
Number of subjects: 299
Study 21967070 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 299
Study 19147374 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic taping (Kinesio Tex)
Number of subjects: 17
Study 19147374 — intervention group
Group type: COMPARATOR
Intervention: Placebo taping (3M Micropore tape)
Number of subjects: 17
Study 17107257 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (25 mg/day)
Number of subjects: 314
Study 17107257 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg/day)
Number of subjects: 314
Study 17107257 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous dosing of sertraline
Number of subjects: 314
Study 17107257 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-onset dosing of sertraline
Number of subjects: 314
Study 17107257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 14612478 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (100 microg/kg and 10 microg/kg per hour) for 7 days
Number of subjects: 150
Study 14612478 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion for 7 days
Number of subjects: 150
Study 11113047 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention in patients with renal failure
Number of subjects: 362
Study 11113047 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with normal renal function)
Number of subjects: 362
Study 11113047 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term outcomes in renal failure patients
Number of subjects: 362
Study 11113047 — intervention group
Group type: COMPARATOR
Intervention: Long-term outcomes in control group (age- and sex-matched)
Number of subjects: 362
Study 8636558 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 116
Study 8636558 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 116
Study 1637970 — intervention group
Group type: EXPERIMENTAL
Intervention: Tree-structured relative risk estimates for censored survival data
Number of subjects: 0
Study 1637970 — intervention group
Group type: COMPARATOR
Intervention: Tree-structured survival methods proposed by Davis and Anderson
Number of subjects: 0
Study 1637970 — intervention group
Group type: COMPARATOR
Intervention: Tree-structured survival methods proposed by Therneau, Grambsch, and Fleming
Number of subjects: 0
Study 6380335 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose-insulin-potassium (GIK) infusion for at least 4 hours after surgery
Number of subjects: 33
Study 6380335 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose-insulin-potassium (GIK) infusion
Number of subjects: 33
Study 6380335 — intervention group
Group type: COMPARATOR
Intervention: Non-GIK treatment
Number of subjects: 33
Study 30943227 — intervention group
Group type: EXPERIMENTAL
Intervention: Gummy candy containing 50 mg of ubiquinol, twice daily for 8 weeks
Number of subjects: 40
Study 28176893 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY)
Number of subjects: 510
Study 28176893 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol/fluticasone combination (SFC)
Number of subjects: 510
Study 25523837 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg·kg(‐1) iv (Group D)
Number of subjects: 141
Study 25523837 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group S)
Number of subjects: 141
Study 23974384 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategy incorporating patient feedback
Number of subjects: 540
Study 23974384 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient feedback on reasons for trial refusal
Number of subjects: 540
Study 20801464 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (75-300 mg/d)
Number of subjects: 259
Study 20801464 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20-60 mg/d)
Number of subjects: 259
Study 20801464 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER
Number of subjects: 259
Study 20801464 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER and Fluoxetine
Number of subjects: 259
Study 19841299 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost 1 ng kg(‐1) min(‐1) administered intravenously 30 to 90 minutes before and ending 4 hours after the procedure
Number of subjects: 208